Drug Trial Radar · NCT03781063
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Sep 20, 2019
Primary completion
May 8, 2025
Study completion May 8, 2025
Sponsor
- Lead sponsor
- Sermonix Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Linical Accelovance Group
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor. The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The secondary objectives are to evaluate: 1. Clinical benefit rate (CBR) and Objective Response Rate (ORR) 2. Duration of response 3. Time to response 4. Overall Survival (OS) 5. Pharmacokinetics of lasofoxifene 6. Quality of life (QoL): Quality of Life (QoL): vaginal assessment scale (VAS) and vulvar assessment scale (VuAS) questionnaires 7. Safety of lasofoxifene 8. Response to various ESR1 mutation (Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N).
Conditions
- Locally Advanced or Metastatic Breast Cancer
Interventions
LasofoxifeneDrug
Estrogen receptor antagonist antineoplastic agent
FulvestrantDrug
Estrogen receptor antagonist antineoplastic agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: through study completion, an average of 1 year
Locations
51 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Yuma Regional Medical Center (JIT)
Yuma, Arizona
City of Hope Comprehensive Cancer
Duarte, California
Compassionate Care Research Group
Fountain Valley, California
UCSF Cancer Center
San Francisco, California
Rocky Mountain Cancer Centers
Longmont, Colorado
Mayo Clinic Florida
Jacksonville, Florida
Miami Cancer Institute
Miami, Florida
Ocala Oncology Center (JIT)
Oscala, Florida
Florida Cancer Specialists
Tallahassee, Florida
The Bond Clinic Cancer & Research Center.
Winter Haven, Florida
Emory University
Atlanta, Georgia
Hawaii Cancer Care (JIT)
Honolulu, Hawaii
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
Illinois Cancer Care (JIT)
Peoria, Illinois
Carle Cancer Center
Urbana, Illinois
Beacon Health (JIT)
South Bend, Indiana
University of Louisville / James Graham Brown Cancer Center
Louisville, Kentucky
FMH James M Stockman Cancer Institute (JIT)
Frederick, Maryland
Mayo Clinic
Rochester, Minnesota
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi
Saint Luke's Cancer Institute
Kansas City, Missouri
HCA Midwest Health
Kansas City, Missouri
Washington University School of Medicine
St Louis, Missouri
Comprehensive Cancer Centers of Nevada (JIT)
Las Vegas, Nevada
New Jersey Cancer Care and Blood Disorders (JIT)
Belleville, New Jersey
Summit Medical Group (JIT)
Florham Park, New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Duke University Medical Center
Durham, North Carolina
TriHealth Cancer Institute
Cincinnati, Ohio
The Ohio State University - Comprehensive Cancer Center
Columbus, Ohio
Ohio Health (JIT)
Columbus, Ohio
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Sanford Cancer Center (JIT)
Sioux Falls, South Dakota
Tennessee Oncology Chattanooga
Chattanooga, Tennessee
West Cancer Center
Germantown, Tennessee
Tennessee Oncology/SCRI
Nashville, Tennessee
Mary Crowley Cancer Research (JIT)
Dallas, Texas
Oncology Consultants (JIT)
Houston, Texas
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.